SOLICITATION NOTICE
A -- Development of Antibodies Specific for Binding New Biomarkers of Exposure to Cholinesterase Inhibitors.”
- Notice Date
- 4/4/2013
- Notice Type
- Presolicitation
- NAICS
- 611310
— Colleges, Universities, and Professional Schools
- Contracting Office
- Department of Health and Human Services, Centers for Disease Control and Prevention, Procurement and Grants Office (Atlanta), 2920 Brandywine Road, Room 3000, Atlanta, Georgia, 30341-4146
- ZIP Code
- 30341-4146
- Solicitation Number
- 2013-N-15033
- Archive Date
- 5/4/2013
- Point of Contact
- Liubov A. Kriel, Phone: 7704882856
- E-Mail Address
-
vyh1@cdc.gov
(vyh1@cdc.gov)
- Small Business Set-Aside
- N/A
- Description
- The Centers for Disease Control and Prevention (CDC)/ National Center for Environmental Health (NCEH)/ Division of Laboratory Sciences (DLS)/ Emergency Response Branch (ERB) intends to award a sole source contract to the University of Nebraska Medical Center, Eppley Institute, Department of Biochemistry & Molecular Biology - Environmental Health & Toxicology, Organophosphorus Toxicity & Cholinesterase Treatment Laboratory, 985950 Nebraska Medical Center, Omaha, NE 68198-5950, for the acquisition of the effort entitled, "Development of Antibodies Specific for Binding New Biomarkers of Exposure to Cholinesterase Inhibitors." The statutory authority for this sole source acquisition is 10 U.S.C 2304(c)(1) in accordance with FAR Part 6.302-1- only one responsible source and no other supplies or services will satisfy the agency requirement. The NAICS code for this procurement is 611310, Colleges, Universities, and Professional Schools. The purpose of this acquisition is to identify and develop monoclonal antibodies specific for binding new long-term protein biomarkers for assessing exposure to cholinesterase inhibitors in clinical samples. The result of this project will be incorporated in the methodology used within the CDC/NCEH/DLS/ERB/CT Method Development Laboratory for the assessment of human exposure to organophosphorus nerve agents. The University of Nebraska Medical Center (UNMC) is the only laboratory to meet all the requirements of the effort. UNMC has access to human clinical samples including serum/plasma and whole blood inhibited by organophosphorus compounds including nerve agents, jet engine lubricant additives, and organophosphorus pesticides; such access to samples is an absolute requirement for developing monoclonal antibodies specific for binding to new protein biomarkers. This lab is a respected, international leader in the field of cholinesterases and has a proven track record for developing new monoclonal antibodies for binding protein biomarkers of exposure to cholinesterase inhibitors. This lab also has a proven track record demonstrating their ability to generate large amounts of native, highly purified cholinesterase inhibitor biomarker proteins and is the world leader in the large scale purification of native butyrylcholinesterase that retains enzymatic activity from clinical samples. Such skills are a necessity for antibody development and screening in this project. Additionally, this laboratory has years of experience maintaining viability of monoclonal antibody producing hybridoma cell lines in the long term which is critical for this work. This laboratory is the only one capable of testing any new monoclonal antibodies that are developed using the same immunomagnetic separation (IMS) liquid chromatography-tandem mass spectrometry (LC-MS/MS) approach that is utilized in CDC's clinical assays for assessing exposure to OPNAs. The Organophosphorus Toxicity & Cholinesterase Treatment Laboratory of the Eppley Institute at the University of Nebraska Medical Center is the primary contributor to monoclonal antibody development in this field and is the only resource that satisfies all of the requirements for this request. As a result of this synopsis, no competitive solicitation will be posted on FedBizOpps. We will issue only one solicitation to the University of Nebraska Medical Center. However, firms that believe they can meet these requirements are encouraged to identify themselves and give written notice by providing a capability statement to the Contract Specialist by April 19, 2013. The Contract Specialist will not respond to verbal request. All requests must be in writing. A determination by the Government not to compete this proposed action will be based on responses to this notice and are solely within the discretion of the Contracting Officer. Information received will be considered solely for the purpose of determining whether to conduct a competitive procurement. Inquiries shall be sent to Liubov Kriel by email at vyh1@cdc.gov and reference solicitation number 2013-N-15033 on the subject line.
- Web Link
-
FBO.gov Permalink
(https://www.fbo.gov/spg/HHS/CDCP/PGOA/2013-N-15033/listing.html)
- Place of Performance
- Address: Contractor's Facility, Omaha, Nebraska, United States
- Record
- SN03028863-W 20130406/130404234822-320ef594024726410c90a30c47c55567 (fbodaily.com)
- Source
-
FedBizOpps Link to This Notice
(may not be valid after Archive Date)
| FSG Index | This Issue's Index | Today's FBO Daily Index Page |